Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance · Aug 19, 2026 · Chemomab Therapeutics Ltd DRC (CMMB)
Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with substantial unmet need—nebokitug could potentially be the first novel mechanism RA therapy approved in the U.S. since 2012 Scipher’s AI Network Medicine platform identified first-in-class CCL24-blocker nebokitug as the highest ranked clinical-stage candidate for RA, potentially providing
Not investment advice. Cached headline, not a full reprint.